FirstWord, a business intelligence resource targeting the international pharmaceutical industry, recently published an in-depth report on managing investigator-initiated research (IIR). Our very own Ran Frenkel, vice president of International Business Development, was interviewed and quoted in the report.
“There are many legal and operational questions [small-to-midsize companies] don’t know how to address, so they just make their best assumptions … It exposes both them as a pharmaceutical company and the sponsor-investigator to unnecessary risks.” – Ran Frenkel, vice-president, International Business Development, Clinipace Worldwide
This comprehensive report brings together industry data, exclusive expert opinions, and a wealth of practical know-how. After a thorough overview of IIR’s recent changes and challenges, the report provides actionable recommendations on every aspect of IIR, from transparent, consistent processes for registration and review of submissions; to compliant, productive sponsor-grantor communications; to clear and regular reporting of what has been achieved.
The report includes considerable input from the board members of the Investigator Initiated Sponsored Research Association (IISRA), as well as exclusive opinions from pharma and investigators.
This report targets managers and executives with responsibilities in:
- Investigator-initiated research (IIR) programs
- Branding and Marketing
- Medical Affairs
- Medical Science Liaisons (MSLs)
For more information, or to order your copy of the report, please visit http://www.firstwordplus.com/managing_investigator_initiated_research.do.